Iron (Monoferric, Ferinject and Venofer) Order Form *TWO PAGES*



Send completed form to Coverdale Infusion Clinics: Fax:1-888-236-3502 or by email: enrollment@coverdaleclinic.com

An infusion fee will apply and is payable by credit card to the Coverdale Resource Center at the time of booking. Please note that a cancellation fee may also apply

PATIENT INFOR					oking. I touse note that a cancella	, эрру			
Patient Name:			DOB (dd/mm/yyyy):	Patient Address:	Patient Address:				
Patient Allergies:		Patient Phone Number:	Patient Email:	Patient Email: Patient H Card Nur					
Emergency Contac	t Name:		Emergency Contact Pho	Emergency Contact Phone Number:		Patient has private insurance coverage? ☐ Yes ☐ No			
PATIENT CLINIC	CAL DETAILS								
Diagnosis:		Hemoglobin: (g/L)							
Patient Weight (k				(dd/mm/yyyy):		First Iron Infusion? ☐ Yes ☐ No			
Relevant Medica	l History/Notes:								
PRESCRIBER IN	IFORMATION								
Prescribing Physici	rescribing Physician Name: Prescribing Physician License #:				Address:				
Prescriber Phone N	criber Phone Number: Prescriber Fax Number:			per:		Email:			
PRESCRIPTIO	N INFORMATI	ON							
	N	10NOFERRIC:	Adult or Off label Pe	diatric *see pedia	tric section below				
□ Adult Protocol Infusion Dose (select one): □ 500 mg □ 1000 mg □ 1500 mg □ Other: 20 mg/kg =mg □ Adult Protocol IV Bolus Injection Administer mg (up to 500 mg) of Monoferric once per week at a rate of up to 250 mg/minute.									
For each total dose (select one): Administer as a single dose (if the total exceeds 20mg/kg or 1500mg, the dose must be split into two infusions at least one week apart. It is recommended, when possible, to give 20mg/kg in the first infusion) Split dosing required (please specify): Day 0:mg, Day:mg Frequency of dose (select one): One-time dose Repeat Dosing Schedule: Administer # infusions at a frequency of: \ Weekly \ Every 2 weeks \ Monthly \ Other: Note: Prescribing physician is responsible for monitoring bloodwork and notifying Coverdale when no further treatment is required. Off label: \ Pediatric Protocol (SickKids Protocol below): Ordered Dose:mg If nauses or reaction occurs, nurse may administer: DimenHYDRINATE 1 mg/kg (up to 50 mg) × 1 dose while in clinic Infuse slowly over 2 hours, titrating as tolerated. Monitor vitals every 15 minutes. Post-infusion observation: 30 minutes (or per nursing judgement). Frequency For each total dose (select one): Administer as a single dose (if the total exceeds 20mg/kg or 1500mg, the dose must be split into two infusions at least one week apart. It is recommended, when possible, to give 20mg/kg in the first infusion) Split dosing required (please specify): Day 0:mg, Day:mg Frequency of dose (select one): One-time dose Repeat Dosing Schedule: Administer # infusions at a frequency of: \ Weekly \ Every 2 weeks \ Monthly \ Other: Note: Prescribing physician is responsible for monitoring bloodwork and notifying Coverdale when no further treatment is required.									
PRE-MEDICATION									
□ None required □ Other: FERINJECT: Adult or Pediatric									
☐ Intravenous Infusion (diluted in sterile 0.9% Sodium Chloride as per manufacturer's recommendations) ☐ Intravenous Injection (undiluted) Dose (Select one or write dose below):									
			nation of the Total I						
Hb (g/L)	Bodyweig		Bodyweight 35	-	Bodyweight ≥7	_			
<100		0 mg	□1500 m	•	□2000 mg				
100 to <140		0 mg	□1000 m	J	□1500 mg				
≥140									
1 1		Determination	n of the Total Iron Need	- Pediatric Ages	1 to 17 Years				

Iron (Monoferric, Ferinject and Venofer) Order Form *TWO PAGES*

Bodyweight 20kg

Hb (g/L)

Bodyweight 10 kg



Bodyweight 60kg

 $Send\ completed\ form\ to\ Coverdale\ Infusion\ Clinics:\ Fax: 1-888-236-3502\ or\ by\ email:\ enrollment @coverdale\ clinic.com$

Bodyweight 30kg

An infusion fee will apply and is payable by credit card to the Coverdale Resource Center at the time of booking. Please note that a cancellation fee may also apply.

Bodyweight 40kg

Bodyweight 50kg

70	□ 300 mg	□ 600 mg	□ 900 mg	□ 1200 mg	□ 1350 mg	□ 1500 mg				
90	□ 250 mg	□ 500 mg	□ 750 mg	□ 1100 mg	□ 1200 mg	□ 1350 mg				
110	□ 200 mg	□ 400 mg	□ 600 mg	□ 900 mg	□ 1000 mg	□ 1100 mg				
130	□ 150 mg	□ 300 mg	□ 450 mg	□ 700 mg	□ 750 mg	□ 800 mg				
≥150	□ 150 mg	□ 300 mg	□ 450 mg	□ 500 mg	□ 500 mg	□ 500 mg				
□ Other: mg Based on the total iron requirement, administer FERINJECT as follows: Max single dose: 15 mg iron/kg body weight or 1000 mg (adults)/750 mg (pediatric). Max weekly dose: 1000 mg (adults) and 750 mg (pediatric). Pregnancy dosing (≥16 weeks): Max dose – 1000 mg (Hb > 90), 1500 mg (Hb ≤ 90).										
Frequency: One-time dose (if dose is >1000mg (adults) or 750mg (pediatric), the dose must be split into two doses at least 7 days apart). Split dosing required (please specify): Day 0:mg, Day:mg Reassess Hb levels no sooner than 4 weeks after the final dose. If additional iron is needed, recalculate the required dose and submit a new medical order.										
PRE-MEDICATIONS										
□ None required □ Other:										
VENOFER: Adults or Off label Pediatric *see pediatric section below										
Length of infusion: Infuse IV over minutes Dose and route: mg IV										
Frequency of dosing: Administer every (days/weeks/months) x doses										
PRE-MEDICATI	IONS									
□ None require	d DOther:									
Pregnancy Considerations:										
Is patient pregnant? ☐ No ☐ Yes – If yes, by proceeding, you acknowledge that Monoferric, Venofer and Ferinject should only be used during pregnancy from gestation week 16 onward (specified in the Monoferric and Ferinject Product Monographs), when the benefit outweighs the risk to both mother and fetus, as per the Product Monograph. You have discussed the risks with the patient/guardian and wish to proceed. Pregnancy dosing (≥16 weeks): Max dose – 1000 mg (Hb > 90), 1500 mg (Hb ≤ 90). Please specify infusion parameters for pregnant patients: Start infusion slow for minutes, slowly titrate up to infuse over minutes as tolerated. Monitor vital signs every minutes. Post-infusion monitoring: minutes.										
Pediatric Considerations:										
Pediatric Use Acknowledgement (MONOFERRIC and VENOFER): As per the Monoferric/Venofer Product Monograph, this medication has not been studied in pediatric populations and is not authorized by Health Canada for pediatric use. By signing below, you confirm that the risks have been discussed with the patient/guardian and that you wish to proceed with treatment as ordered. Please indicate any additional protocols:										
I authorize Coverdale Resource Centre to act as my designated agent to forward this prescription to the pharmacy chosen by the patient named above. This prescription is the original order and is intended solely for the patient's selected pharmacy.										
Prescriber S	Prescriber Signature: Date (dd/mm/yyyy):									